BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31317804)

  • 21. The Potentially Significant Role of CYP3A-Mediated Oxidative Metabolism of Dabigatran Etexilate and Its Intermediate Metabolites in Drug-Drug Interaction Assessments Using Microdose Dabigatran Etexilate.
    Udomnilobol U; Jianmongkol S; Prueksaritanont T
    Drug Metab Dispos; 2023 Sep; 51(9):1216-1226. PubMed ID: 37230768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin.
    Choi JS; Piao YJ; Kang KW
    Arch Pharm Res; 2011 Apr; 34(4):607-13. PubMed ID: 21544726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Grapefruit juice activates P-glycoprotein-mediated drug transport.
    Soldner A; Christians U; Susanto M; Wacher VJ; Silverman JA; Benet LZ
    Pharm Res; 1999 Apr; 16(4):478-85. PubMed ID: 10227700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir.
    Kharasch ED; Stubbert K
    Drug Metab Dispos; 2013 Dec; 41(12):2166-74. PubMed ID: 24067429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased intestinal CYP3A and P-glycoprotein activities in rats with adjuvant arthritis.
    Uno S; Kawase A; Tsuji A; Tanino T; Iwaki M
    Drug Metab Pharmacokinet; 2007 Aug; 22(4):313-21. PubMed ID: 17827786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
    Raeissi SD; Hidalgo IJ; Segura-Aguilar J; Artursson P
    Pharm Res; 1999 May; 16(5):625-32. PubMed ID: 10350002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin.
    Choi SJ; Shin SC; Choi JS
    Arch Pharm Res; 2011 Feb; 34(2):309-15. PubMed ID: 21380815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine.
    Lagas JS; Damen CW; van Waterschoot RA; Iusuf D; Beijnen JH; Schinkel AH
    Mol Pharmacol; 2012 Oct; 82(4):636-44. PubMed ID: 22767610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    J Clin Pharmacol; 2005 Jan; 45(1):79-88. PubMed ID: 15601808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
    Kim RB; Wandel C; Leake B; Cvetkovic M; Fromm MF; Dempsey PJ; Roden MM; Belas F; Chaudhary AK; Roden DM; Wood AJ; Wilkinson GR
    Pharm Res; 1999 Mar; 16(3):408-14. PubMed ID: 10213372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive assessment of Cucurbitacin E related hepatotoxicity and drug-drug interactions involving CYP3A and P-glycoprotein.
    Lu J; Zhang Y; Sun M; Liu M; Wang X
    Phytomedicine; 2017 Mar; 26():1-10. PubMed ID: 28257659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of oral curcumin on the pharmacokinetics of intravenous and oral etoposide in rats: possible role of intestinal CYP3A and P-gp inhibition by curcumin.
    Lee CK; Ki SH; Choi JS
    Biopharm Drug Dispos; 2011 May; 32(4):245-51. PubMed ID: 21506134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism.
    Dufek MB; Knight BM; Bridges AS; Thakker DR
    Drug Metab Dispos; 2013 Mar; 41(3):642-50. PubMed ID: 23288866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells.
    Ikemura K; Urano K; Matsuda H; Mizutani H; Iwamoto T; Okuda M
    J Pharmacol Exp Ther; 2009 Jan; 328(1):249-55. PubMed ID: 18842703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using felodipine and hesperetin in combination in Wistar rats and everted rat gut sacs in vitro.
    Sridhar V; Surya Sandeep M; Ravindra Babu P; Naveen Babu K
    Phytother Res; 2014 May; 28(5):699-705. PubMed ID: 23881850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone.
    Zhu L; Yang X; Zhou J; Tang L; Xia B; Hu M; Zhou F; Liu Z
    Food Chem Toxicol; 2013 Jan; 51():396-403. PubMed ID: 23085095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects.
    Robertson SM; Davey RT; Voell J; Formentini E; Alfaro RM; Penzak SR
    Curr Med Res Opin; 2008 Feb; 24(2):591-9. PubMed ID: 18205997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats.
    Hirunpanich V; Murakoso K; Sato H
    Int J Pharm; 2008 Mar; 351(1-2):133-43. PubMed ID: 18082981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Baicalin reduces ciclosporin bioavailability by inducing intestinal p-glycoprotein in rats.
    Tian X; Chang Y; Wei J; Liu R; Wang L; Zhang J; Zhang X
    J Pharm Pharmacol; 2019 May; 71(5):788-796. PubMed ID: 30663770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.
    Abuasal BS; Bolger MB; Walker DK; Kaddoumi A
    Mol Pharm; 2012 Mar; 9(3):492-504. PubMed ID: 22264132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.